WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization, congratulates its strategic partner, Amicus Therapeutics, on receiving U.S. FDA’s approval for Pombiliti™ + Opfolda™ 65mg capsules.